Trichostatin A destabilizes HIF-2α through a VHL-independent but proteasome-dependent pathway in cancer cell lines and tumor xenografts

Authors

  • Qingcheng Yang Department of Orthopedics, Sixth People's Hospital, Shanghai JiaoTong University, Shanghai 200233
  • Yuzhen Du Department of Clinical Laboratory, Sixth People’s Hospital, Shanghai JiaoTong University, Shanghai 200233
  • Dongdong Cheng Department of Orthopedics, Sixth People's Hospital, Shanghai JiaoTong University, Shanghai 200233
  • Zhichang Zhang Department of Orthopedics, Sixth People's Hospital, Shanghai JiaoTong University, Shanghai 200233
  • Xinhui Du Department of Orthopedics, Sixth People's Hospital, Shanghai JiaoTong University, Shanghai 200233

DOI:

https://doi.org/10.3329/bjp.v8i2.13842

Keywords:

Cancer cell line, HIF-2α, Proteasome, Trichostatin A, Tumor xenograft, VHL

Abstract

Histone deacetylase (HDACs) inhibitors are a new generation of anti-cancer agents. Little is known regarding the effect of HDAC inhibitors on HIF-2α. The effect of trichostatin A (TSA), a class I/II HDAC inhibitor, on HIF-2α protein expression was investiagted in cancer cell lines and tumor xenografts. Results showed TSA inhibited the HIF-2α protein expression in a dose-dependent manner, which was VHL-independent, but proteasome-dependent in cell lines. In tumor xenografts, TSA inhibited tumor growth and HIF-2α expression. Knocking down of HDAC6 by small RNA interfering decreased HIF-2α protein expression. HDAC6 physically interracted with HIF-2α, and HIF-2α was acetylated by TSA. TSA destabilizes HIF-2α in a proteasome dependent manner, which is unrelated to VHL, suggesting the anticancer effect of TSA is at least partially mediated by its inhibition of HIF-2α, which provides a new insight into the molecular mechanism underlying the anticancer effect of HDAC inhibitors.

Downloads

Download data is not yet available.
Abstract
1560
Download
707 Read
152

References

Bertout JA, Patel SA, Simon MC. The impact of oxygen availability on human cancer. Nat Rev Cancer. 2008; 8: 967-75.

Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004; 73: 417-35.

Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 2000; 6: 389-95.

Caro J. Hypoxia regulation of gene transcription. High Alt Med Biol. 2001; 2: 145-54.

Chen S, Sang N. Histone deacetylase inhibitors: The epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol. 2011; 2011: 197946.

de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003; 370: 737-49.

Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009; 324: 1289-93.

Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195: 1-16.

Fath DM, Kong X, Liang D, Lin Z, Chou A, Jiang Y, Fang J, Caro J, Sang N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem. 2006; 281: 13612-19.

Fraisi P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism Dev Cell. 2009; 16: 97-106.

Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15-23.

Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001; 28: 36-41.

Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 2006; 10: 413-23.

Kim HJ, Bae SC. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3: 166-79.

Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7: 437-43.

Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006; 26: 2019-28.

Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle. 2006; 5: 2430-35.

Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 2003; 3: 75-88.

Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods Enzymol. 2007; 435: 385-402.

Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ. 2008; 15: 628-34.

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006; 66: 8814-21.

Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004; 64: 6626-34.

Qing G, Simon MC. Hypoxia inducible factor-2alpha: A critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev. 2009; 19: 60-65.

Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-34.

Semenza GL. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochem Pharm. 2000; 59: 47-53.

Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008; 60: 591-97.

Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009; 24: 97-106.

Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004; 14: 198-206.

Downloads

Additional Files

Published

2013-03-24

How to Cite

Yang, Q., Y. Du, D. Cheng, Z. Zhang, and X. Du. “Trichostatin A Destabilizes HIF-2α through a VHL-Independent But Proteasome-Dependent Pathway in Cancer Cell Lines and Tumor Xenografts”. Bangladesh Journal of Pharmacology, vol. 8, no. 2, Mar. 2013, pp. 142-8, doi:10.3329/bjp.v8i2.13842.

Issue

Vol. 8 No. 2 (2013)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).